{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of 5-ALA Dosing for Fluorescence-Guided Resection of Malignant Glioma"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "In a double-blind, randomised controlled trial, 21 patients with suspected malignant glioma were enrolled at a single center."
      },
      "Participants": {
        "score": 2,
        "evidence": "Participants aged 18-75 years with a Karnofsky Performance Scale score of \u226570% were randomised to receive 0.2, 2, or 20 mg/kg of 5-ALA."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants aged 18-75 years with a Karnofsky Performance Scale score of \u226570% were randomised to receive 0.2, 2, or 20 mg/kg of 5-ALA."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluates the efficacy of different doses of five-aminolevulinic acid (5-ALA) for fluorescence-guided resection of malignant glioma."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the surgeon's perception of tumor fluorescence under violet-blue light, measured intraoperatively."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was performed using block randomisation with allocation concealment via sealed envelopes."
      },
      "Blinding": {
        "score": 3,
        "evidence": "Blinding included patients, surgeons, and outcome assessors."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "21 patients with suspected malignant glioma were enrolled at a single center."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "All 21 patients completed the study."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "The 20 mg/kg group showed the strongest fluorescence in tumor core and margins, correlating with cell density."
      },
      "Harms": {
        "score": 0,
        "evidence": "Adverse events were not reported."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT02755142."
      },
      "Funding": {
        "score": 1,
        "evidence": "Funding: Sponsored by Medac, Hamburg, Germany."
      }
    },
    "total_score": 21,
    "max_score": 25
  },
  "model": "gpt-4o"
}